MEDI-570
Astrazeneca
['nhl']
our section's fearless leader, dr. , has a new article in 's clinical cancer research regarding the targeting of icos with a specific monoclonal antibody in patients who have relapsed/refractory malignant t-nhl. read the whole article at: 
UChicago's Section of Hematology/Oncology has a long tradition of excellence and is ranked among the finest cancer programs in the country.